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Aims: Despite the remarkable efficacy shown in clinical practice, concerns have been raised 
about the costs associated with direct antiviral agent (DAA) therapy. This article presents the 
real-life costs for DAA treatment sustained by the Italian National Health Service in the Liguria 
Region (Northern Italy).
Methods: A retrospective analysis of the cost per care sustained for DAA treatment, relating 
to the period from January 1 to December 31, 2015 in five centers in Liguria was performed. 
All patients undergoing DAA-based treatments for hepatitis C virus (HCV) infection were 
enrolled. On-treatment costs included: HCV treatment, laboratory test, outpatient services, 
attended visits, drugs used for the management of adverse events (erythropoietin, albumin or 
red blood cell packs) and inpatient service admissions.
Results: In total, 327 patients were enrolled. No difference in terms of sustained virologic 
response (SVR) rate among different treatments was reported. The majority (85.0%) of 
patients did not report any side effects and only 15 (4.6%) required hospital admission. 
Forty-two patients (12.8%) required high-cost drugs for the management of adverse events. 
The overall cost sustained was €14,744,433. DAA±ribavirin (RBV) accounted for the wide 
majority of this cost (98.9%; €14,585,123). Genotype (GT) 1, the most commonly treated 
GT, was associated with an average cost of €43,445 per patient. Detailed analysis of the 
costs for GT 1 showed the treatment based on ritonavir boosted paritaprevir/ombitasvir + 
dasabuvir±RBV with an average cost of €24,978 (RBV+) and €25,448 (RBV−) per patient 
was the most cost-effective. The average cost per SVR was €48,184. Once again, the ritonavir 
boosted  paritaprevir/ombitasvir + dasabuvir regimen was associated with the lowest cost/SVR 
(€25,448/SVR [GT 1b] and similar results for other GTs).
Conclusion: Antiviral regimen is the major contributor to costs in the treatment of HCV infec-
tion. Appropriate regimen selection could result in a major cost saving, which can be reinvested 
to allow more patients to be treated.
Keywords: HCV treatment, HCV costs, cost efficacy
Introduction
Infection by hepatitis C virus (HCV) represents a major health issue. HCV is estimated 
to infect 180 million people worldwide and it is the seventh cause of death globally.1 
More than 2 million Italian individuals have contracted the HCV virus; of note, 20%–
50% of infections are reported in intravenous drug abusers.2–4 The predominant genotype 
(GT) of HCV is 1b, with a higher prevalence in women and elderly, followed by GT 2.5
The main target of antiviral treatment is to reduce the onset of disease complica-
tions, including liver cirrhosis and hepatocellular carcinoma. To this end, antiviral 
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therapy is aimed at achieving eradication of HCV infection, 
that is, a sustained virologic response (SVR).
Interferon-based antiviral therapy resulted in long-term 
success and a reduced mortality.6,7 However, the recent 
introduction of interferon-free regimens based on second-
generation direct antiviral agents (DAAs) led to a dramatic 
improvement in clinical outcomes, with SVR rates >90%. In 
2015, the interferon-free regimens available were: 1) sofos-
buvir + ledipasvir (SOF+LDP),8,9 2) daclatasvir + sofosbu-
vir (SOF+DCV),10–12 3) ombitasvir + paritaprevir/ritonavir 
(PTVr/OBV) + dasabuvir (DSV),13–17 and 4) SOF+simeprevir 
(SOF+SIM).18 All these regimens can be associated, or not, 
with ribavirin (RBV). The treatment schedules defined by 
the Italian Society for Liver Diseases according to the Euro-
pean Association for Liver Diseases are included in Table 
S1. Despite their high efficacy, concerns have been raised 
about the costs associated with DAA therapy. With respect 
to the Italian scenario, different budget impact analyses have 
been published, however, considering only the drug cost19 
or the complete treatment path.20 To date, no studies have 
investigated the actual cost sustained by the Italian National 
Health Service (NHS) during the first year of clinical use of 
second-generation DAAs. This manuscript aims to present 
the real-life costs for DAA treatment sustained by the NHS 
in the Liguria Region.
Methods
Study design
In order to achieve the primary objective, a retrospective 
analysis of the cost per care sustained for DAA treat-
ment, in the period from January 1 to December 31, 2015 
(Northern Italy), was conducted in the Liguria Region. Six 
centers, linked in a network, were involved: Infectious Dis-
ease Unit, San Remo; ASL 2 Infectious Disease Unit, San 
Paolo Hospital, Savona; Infectio us Disease Unit, Galliera 
Hospital, Genoa; Infectious Disease Clinic, San Martino 
Hospital, Genoa; Liver Unit, San Martino Hospital, Genoa 
and Infectious Disease Unit, ASL 5, La Spezia. The study 
was approved by the Regione Liguria ethical committee 
(approval ID 268REG2016). An informed consent form was 
signed by each patient.
All patients undergoing DAA-based regimens for HCV 
infection and reaching the 12-week posttreatment evaluation 
by March 31, 2016 (end of treatment by December 31, 2015) 
were enrolled. Patients belonging to special categories (e.g., 
those in hemodialysis, organ transplant recipients or thalas-
semia major carriers) were excluded due to the high costs 
involved in their underlying disease.
Health care providers generated a list of the subjects 
with HCV who started treatment in the study period, with all 
relevant demographic and treatment details. An automated 
system collected all data from laboratory and administrative 
services on an online platform, in order to obtain data on 
hospitalizations, medical visits and laboratory tests for each 
patient.21,22 The clinicians involved in the study provided 
the final data about the treatment outcome at 12 weeks after 
treatment.
Additional data were recorded on the use of special drugs 
characterized by high cost, such as erythropoietin, albumin 
or red blood cell packs.
Use of resources and costs
On-treatment costs included HCV treatment, laboratory 
tests, outpatient services, attended visits, drugs used for the 
management of adverse events (erythropoietin, albumin 
or red blood cell packs) and inpatient service admissions. 
Hospitalizations were classified by ICD -9 codes, and the 
financial costs considered were those established by the 
Italian NHS.
The drug-related costs of SOF and SOF/LDV are linked 
to a price/volume payback scheme covered by confidential 
agreement.23 However, the Emilia-Romagna Region peri-
odically reports an update of the average costs of each drug 
on its institutional website.24 Therefore, this source at the 
moment represents the most reliable one for the economic 
analysis, and hence was used in this study.25–27 The cost of the 
treatment was defined on the basis of the month of the first 
prescription. Given the contract existing between the Italian 
NHS and pharmaceutical companies, 24 weeks of treatment 
have the same cost as 12 weeks (Table S2).28
For patients who discontinued treatment for any reason 
before the scheduled end, the following costs were attributed: 
1) within 4 weeks, one-third of 12-week treatment; 2) within 
8 weeks, two-thirds of 12-week treatment and 3) >8 weeks, 
the same as 12-week treatment.
The costs attributed to each additional procedure, 
including treatment with RBV and erythropoietin, were 
those defined by the Liguria Region for the year 2015 
(Table S3).29–31 However, albumin and red cell blood pack-
related costs were not included because they were admin-
istered during hospital admission and hence were already 
considered in diagnosis related group reimbursement for the 
hospital stay from patients’ perspective (Tables S4 and S5).32
The cost per SVR was defined as the total cost for each 
regimen divided by the number of SVR observed for that 
specific regimen.




Cost per care of DAAs in Linguria
According to the Italian Drug Agency (AIFA), DAAs are 
fully reimbursable only for subjects affected by METAVIR 
fibrosis at F3 or F4 stage or those with lower fibrosis but pre-
senting an extrahepatic disease (malignant lymphoma, HCV-
related vasculitis and symptomatic cryoglobulinemia).28,33 
These rules have been summarized in the six criteria defined 
by AIFA as follows: 1) patients with liver cirrhosis Child Pugh 
A or B and/or HCC with complete treatment; 2) patients with 
recurrence of HCV infection after liver transplantation with 
a METAVIR score >2; 3) patients with chronic hepatitis and 
serious extrahepatic liver diseases (malignant lymphoma, 
HCV-related vasculitis and symptomatic cryoglobulinemia); 
4) patients with chronic hepatitis C and METAVIR F3; 5) 
patients on the waiting list for liver transplantation and 6) 
patients with chronic hepatitis C and solid organ transplanta-
tion (different from liver) or bone with fibrosis METAVIR >2.
Statistical analysis
Data were analyzed by descriptive statistics. Demographic 
and clinical characteristics were also reported according to the 
HCV treatment. Differences in categorical variables were com-
pared with the chi-squared test or Fisher’s exact test, whereas 
continuous variables were compared with analysis of variance 
or Kruskal–Wallis test, as appropriate. Normality of continu-
ous variables was tested using Kolmogorov–Smirnov test.
To account for the different prices of HCV treatments 
during the year (depending on treatment initiation) and to 
control simultaneously for the possible confounding effect of 
different variables, a multivariate linear regression analysis 
was performed. Only the variables with a univariate p<0.05 
were introduced in the model.
A univariate sensitivity analysis was conducted to deter-
mine the impact of the SVR rate, HCV treatment prices, and 
direct cost on the cost-per SVR. The rate of SVR varied over 
a range of 2%–5%, the anti-HCV treatment prices varied 
over a range of 10%–50%, and direct costs varied over a 
range of 10%–30%.
A p-value <0.05 was considered significant. Analyses 
were performed by R software.
Results
Population
In total, 327 patients were enrolled, covering 49% of all 
DAA-based regimens started in 2015 in the involved center 
(cut-off: December 31, 2015). The remaining 51% were 
those not meeting the inclusion criteria, mainly the patients 
who were still undergoing treatment or did not reach the 
12-week posttreatment evaluation point by March 31, 2016. 
The demographic and clinical details are presented in Table 1. 
The majority of patients were males (71%) living in Liguria 
(97%) and had been already treated for HCV (53%; Table 
1). The rate of SVR at 12 weeks posttreatment was 93.5% 
(n=306). Among the 21 patients who did not reach this goal, 
a relapse was observed in 11 (52%), a vital breakthrough in 2 
(9%), treatment interruption in 5 (24%), death (between the 
end of treatment and the 12 weeks time point) in 2 (9%) and 
failure in 1 (5%) patient. Reasons for treatment interruption 
were: two deceased, toxicity in two patients and personal 
decision in the last one. The main clinical features according 
to the treatment prescribed are shown in Table S6.
SVR rates
No differences in terms of SVR rate among different treat-
ments were reported (Table 2). A detailed analysis of the 
SVR according to HCV GT showed a significant difference 
Table 1 Clinical and demographic features at baseline





 San Martino – UOS epatologia 114 (34.86)
 San Martino – Clinica Malattie Infettive 61 (18.65)
 La Spezia – SC Malattie Infettive 57 (17.43)
 Genova – Galliera SC Malattie Infettive 47 (14.37)
 Sanremo – SC Malattie Infettive 36 (11.01)
 Savona – SC Malattie Infettive 12 (3.67)
Resident in Regione Liguria 318 (97.25)
Gender
 Male 233 (71.25)
 Female 94 (28.75)
Age, years 57.11±9.72 
HCV treatment details
 Previous treatment 174 (53.21)
Criteria for prescription according to Italian Drugs Agency
 1 251 (76.76)
 2 1 (0.31)
 3 14 (4.28)
 4 60 (18.35)
 6 1 (0.31)
Genotype
 1a 80 (24.46)
 1b 94 (28.75)
 2 31 (9.48)
 3 78 (23.85)
 4 44 (13.46)
Fibrosis stage
 F1 4 (1.22)
 F2 6 (1.83)
 F3 64 (19.57)
 F4 253 (77.37)
(Continued)





between GT 3 (SVR 85.9%) and other GTs. GT 1 is the most 
susceptible to treatment with DAA, with an overall SVR rate 
of 95.9%, while GT 2 and GT 4 were associated with an over-
all SVR rate of 96.7% and 95.4%, respectively. A combined 
analysis of treatment and regimen confirms these findings. In 
GT 1b-infected patients, the SVR rate ranged from 90.9% to 
100%, according to the regimen prescribed. Very similar rates 
were observed in GT 1a (from 93.7% to 100%), GT 2 (96.7%) 
and GT 4 (from 92.3% to 100%; Table 2). On the other hand, 
GT 3 was associated with an SVR rate ranging from 82.2% 
to 100%, according to therapy. DCV was available in Italy 
later than in other European countries, and therefore, our 
study (aimed at the description of the first year of treatment 
in Liguria) included only a small quote of patients affected 
by GT 3 treated with this molecule; the only combination 
available was SOF and RBV.
Adverse events
The majority (85.0%) of patients did not present any side 
effects, and only 15 (4.6%) patients required hospital 
admission; the median length of hospital stay was 11 days 
(interquartile range: 3–18 days). Forty-two (12.8%) patients 
required high-cost drugs for the management of adverse 
events: erythropoietin was necessary in 39 (11.9%) patients, 
albumin in 5 (1.5%) patients and red blood cell packs in 3 
(1%) patients; and 3 patients required 2 of these treatments 
and 1 patient required all of them.
Pharmacoeconomic analysis
The overall cost sustained for the treatment of 327 patients 
was €14,744,433. DAA±RBV accounted for the highest 
proportion of cost (98.9%; €14,585,123), followed by the 
Features All patients, 
absolute value 
(%) (N=327)
Child Pugh (only for fibrosis stage 4)* 
 Child A 228 (90.12)
 Child B 24 (9.49)
 Child C 1 (0.40)
Treatment regimen
 SOF+RBV 76 (23.24)
 SOF+LDP+RBV 52 (15.90)
 SOF+SIM+RBV 51 (15.60)
 PTVr/OBV+DSV+RBV 44 (13.46)
 SOF+DCV+RBV 36 (11.01)
 SOF+SIM 26 (7.95)
 SOF+LDP 16 (4.89)
 PTVr/OBV+RBV 10 (3.06)
 PTVr/OBV+DSV 9 (2.75)
 SOF+DCV 7 (2.14)
Length of treatment (weeks) 15.87±5.75
Comorbidities
 Patients presenting with at least one comorbidity 168 (51.38)
Number
 No comorbidity 159 (48.62)
 1 comorbidity 85 (25.99)
 2 comorbidities 59 (18.04)
 ≥3 Comorbidities 24 (7.34)
Comorbidities
 Drug abuse 104 (31.80)
 HIV infection 74 (22.63)
 Heart disease 52 (15.90)
 Metabolic syndrome 34 (10.40)
 Renal disease 10 (3.06)
 HBV infection 3 (0.92)
Notes: *% Calculated in patients with fibrosis stage F4. Data are presented as: 
continuous variables: mean±SD; categorical variables: n (%).
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; HIV, 
human immunodeficiency virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir 
boosted paritaprevir; RBV, ribavirin; SD, standard deviation; SIM, simeprevir; 
SOF, sofosbuvir; UOS, Unità Operativa Semplice; SC, Struttura Complessa; HBV, 
hepatitis B chronic infection.
Table 1 (Continued)
Table 2 SVR rate according to genotype and regimen prescribed
 Regimen anti-HCV
 prescribed 
Genotype 1 Genotype 1a Genotype 1b Genotype 2 Genotype 3 Genotype 4 Total
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
SOF+RBV   30/31 (96.77) 37/45 (82.22)  67/76 (88.16)
SOF+LDP+RBV 43/45 (95.56) 30/32 (93.75) 13/13 (100.00)   7/7 (100.00) 50/52 (96.15)
SOF+SIM+RBV 35/38 (92.11) 15/16 (93.75) 20/22 (90.91)   12/13 (92.31) 47/51 (92.16)
PTVr/OBV+DSV+RBV 42/44 (95.45) 13/14 (92.86) 29/30 (96.67)    42/44 (95.45)
SOF+DCV+RBV 3/3 (100.00) 2/2 (100.00) 1/1 (100.00)  26/29 (89.66) 4/4 (100.00) 33/36 (91.67)
SOF+SIM 21/21 (100.00) 9/9 (100.00) 12/12 (100.00)   5/5 (100.00) 26/26 (100.00)
SOF+LDP 12/12 (100.00) 6/6 (100.00) 6/6 (100.00)   4/4 (100.00) 16/16 (100.00)
PTVr/OBV+RBV     9/10 (90.00) 9/10 (90.00)
PTVr/OBV+DSV 9/9 (100.00)  9/9 (100.00)    9/9 (100.00)
SOF+DCV 2/2 (100.00) 1/1 (100.00) 1/1 (100.00)  4/4 (100.00) 1/1 (100.00) 7/7 (100.00)
Total 167/174 (95.98) 76/80 (95.00) 91/94 (96.81) 30/31 (96.77) 67/78 (85.90) 42/44 (95.45) 306/327 (93.58)
p‑value 0.90 1.00 0.81  ‑ 0.74 1.00 0.56
Note: Italics indicate data on GT 1a/b.
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; GT, genotype; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; RBV, 
ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virologic response.
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management of adverse events (hospital admissions and 
high-cost drugs for treatment support; €89,078; 0.6%). A 
marginal impact was attributed to laboratory analysis and 
outpatient service visits (€38,180, 0.26% and €32,053, 
0.22%, respectively).
When the average costs per care were evaluated accord-
ing to the GT, GT 2 was the one absorbing the lowest 
resources, while GT 3 and GT 4 were those with higher 
costs per patient (Table 3). GT 1, the most commonly treated 
GT (174 patients), was associated with an average cost of 
€43,445 per patient. A detailed analysis of the costs of GT 
1 showed the treatment based on PTVr/OBV+DSV±RBV 
with an average cost of €24,978 (with RBV) and €25,448 
(without RBV) per patient was the most economical; on 
the other hand, SOF+SIM+RBV regimen was the most 
expensive, with an average cost of €61,027. Between GT 
1a and GT 1b, an important difference in costs was reported 
(Table 4). In GT 1a treatment, the PTVr/OBV+DSV±RBV 
regimen was associated with the lowest cost, although it was 
prescribed only in 17.5% of cases. On the other hand, the 
PTVr/OBV+DSV±RBV regimen was the most frequently 
prescribed for GT 1b (31.9%/9.6%), and it was associated 
with the lowest cost (Table 5).
Multivariate linear regression model confirmed a signifi-
cant difference in costs of care according to HCV treatment, 
even after adjusting for the clinical characteristics at treat-
ment initiation (Table S7).
The average cost per SVR was €48,184, with negligible 
differences between pretreated patients and naïve subjects. 
Also, the PTVr/OBV+DSV regimen was associated with 
lowest cost per SVR (€25,448 per SVR [GT 1b] and similar 
results for other GTs; Table 6).
Sensitivity analysis (Table 7) confirms the antiviral drug 
cost as the major contributor to the total cost. A second con-
tributor was the achievement of SVR: an increase in SVR 
rate led to a major reduction in cost per SVR.
Discussion
We have reported a detailed analysis of all costs related to 
the first year of use of all oral DAAs for the treatment of 
HCV infection. Our study allowed us to identify the less-
costly options, with possible indications on how to optimize 
the treatment schedule and, hence, treat more patients at 
the same global cost. In our opinion, in a condition of lim-
ited resources available, this is the only strategy that could 
increase the number of treated patients. It is worth nothing 
that our analysis was conducted in a “field-practice” cohort of 
consecutive unselected patients, regardless of comorbidities, 
coinfections, age, gender or prior therapies.
Our results highlight some critical issues: safety, efficacy 
and costs. Overall, SVR was reached in 93.8% of the patients 
treated, a rate that is well-aligned with the current clinical 
experience. The majority of our population was composed of 
patients with more severe fibrosis, as regulated by AIFA that 
allows the prescription of DAAs only to METAVIR F3 or F4 
fibrosis stage.28 Nevertheless, DAA-based regimens were safe 
and effective, with SVR rates in line or even better compared 
with those reported in other real-life studies.34,35 In our study, 
hospital admissions were limited to a small  proportion of 
patients (12.4%). This finding is in contrast with those exist-
ing for the first-generation DAAS – as recorded, for instance, 
in the CUPIC study, where 40% of patients reported a serious 
adverse event requiring hospital admission.36
Anemia requiring support with high-cost drugs was 
observed in 42 patients (12.4%). The PAN study, a large 
German study based on first-generation DAAs, reported 
the same side effect only in 2.4%,37 but in that study, only 
17.3% of the cohort presented an advanced fibrosis or liver 
cirrhosis ( determined by AST to platelet ratio index). In our 
cohort, 77.3% of patients had a METAVIR score F4 defined 
by fibroscan or liver biopsy.37 Therefore, the more advanced 
the liver fibrosis, the higher the risk of anemia, as already 
shown by other studies.38 However, given the current trend 
in reducing the use of RBV,39 the impact of this element will 
be further reduced.
When the evaluation of costs was correlated with SVR 
rate, the two GTs with the lowest SVR rates, namely, GT 3 
and GT 4, were those associated with the highest costs. On 
the other hand, GT 1b was the most frequently reported in our 
cohort – and all over Italy – and therefore, a treatment associ-
ated with a low total cost, such as PTVr/OBV+DSV±RBV 
(€24,978/25,448), could represent an interesting option 
for the reduction of total expense. Moreover, the notable 
difference in average cost reported between GT 1a and GT 
1b could be attributed to the different pattern of treatment. 
Table 3 Total cost and average cost (in €) per patient according 
to genotype
Genotype Patients Total Percentage Mean SD
1 174 7,559,389 51.27 43,445 15,430
1a 80 3,616,227 24.53 45,203 14,034
1b 94 3,943,162 26.74 41,949 16,451
2 31 1,269,035 8.61 40,937 2,620
3 78 3,810,101 25.84 48,847 9,405
4 44 2,105,908 14.28 47,862 15,001
Total 327 14,744,433 100.00 45,090 13,603
p‑value 0.004
Abbreviation: SD, standard deviation.





Table 4 Total and mean costs for different DAA treatments in patients according to HCV genotype Table 4 (Continued)
Anti-HCV regimen Genotype 1 Genotype 2 Genotype 3 Genotype 4
n Total Percentage Mean SD n Total Percentage Mean SD n Total Percentage Mean SD n Total Percentage Mean SD
SOF+RBV      31 1,269,035 40,937 2,620 45 1,855,475 48.70 41,233 630
SOF+LDP+RBV 45 1,886,982 24.96 41,933 7,217 7 300,893 14.29 42,985 5,345
SOF+SIM+RBV 38 2,319,038 30.68 61,027 875 13 787,608 37.40 60,585 992
PTVr/OBV+DSV+RBV 44 1,099,015 4.54 24,978 3,644
SOF+DCV+RBV 3 184,185 2.44 61,395 2,645      29 1,729,192 45.38 59,627 4,071 4 239,213 11.36 59,803 12
SOF+SIM 21 1,254,155 16.59 59,722 3,564 5 299,942 14.24 59,988 1,476
SOF+LDP 12 467,681 6.19 38,973 9,350 4 179,495 8.52 44,874 50
PTVr/OBV+RBV 10 239,209 11.36 23,921 662
PTVr/OBV+DSV 9 229,036 3.03 25,448 0
SOF+DCV 2 119,299 1.58 59,649 0      4 225,434 5.92 56,358 6,448 1 59,548 2.83 59,548 .
Total 174 7,559,389 100.00 43,445 15,430 31 1,269,035 100.00 40,937 2,620 78 3,810,101 100.00 48,847 9,405 44 2,105,908 100.00 47,862 15,001
p‑value <0.0001 – <0.0001 <0.0001
Abbreviations: DAA, direct antiviral agent; DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; 
RBV, ribavirin; SD, standard deviation; SIM, simeprevir; SOF, sofosbuvir.
Table 5 Total cost and average cost (in €) per patient according to genotype and regimen prescribed; focus on genotype 1
Regimen anti-HCV Genotype 1a Genotype 1b
n Total Percentage Mean SD n Total Percentage Mean SD
SOF+RBV
SOF+LDP+RBV 32 1,343,382 37.15 41,981 7,687 13 543,600 13.79 41,815 6,189
SOF+SIM+RBV 16 9,72,878 26.90 60,805 227 22 1,346,160 34.14 61,189 1,116
PTVr/OBV+DSV+RBV 14 3,46,455 9.58 24,747 3,588 30 752,560 19.09 25,085 3,726
SOF+DCV+RBV 2 1,24,269 3.44 62,134 3,272 1 59,916 1.52 59,916 .
SOF+SIM 9 5,42,536 15.00 60,282 1,100 12 711,619 18.05 59,302 4,666
SOF+LDP 6 2,27,058 6.28 37,843 7,748 6 240,622 6.10 40,104 11,369
PTVr/OBV+RBV
PTVr/OBV+DSV 9 229,036 5.81 25,448 0
SOF+DCV 1 59,649 1.65 59,649 1 596,49 1.51 59,649
Total 80 3,616,227 100.00 45,203 14,034 94 3,943,162 100.00 41,949 16,451
p‑value <0.0001 <0.0001
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; RBV, ribavirin; SD, 
standard deviation; SIM, simeprevir; SOF, sofosbuvir.
Table 6 Cost per SVR‑12 (in €) according to genotype and treatment regimen
Anti-HCV regimen Genotype Total
1 1a 1b 2 3 4
SOF+RBV 42,301 50,148 46,634
SOF+LDP+RBV 43,883 44,779 41,815 42,985 43,757
SOF+SIM+RBV 66,258 64,859 67,308 65,634 66,099
PTVr/OBV+DSV+RBV 26,167 26,650 25,950 26,167
SOF+DCV+RBV 61,395 62,135 59,916 66,507 59,803 65,230
SOF+SIM 59,722 60,282 59,302 59,988 59,773
SOF+LDP 38,973 37,843 40,104 44,874 40,448
PTVr/OBV+RBV 26,579 26,579
PTVr/OBV+DSV 25,448 25,448 25,448
SOF+DCV 59,649 59,649 59,649 56,359 59,548 57,754
Total 45,266 47,582 43,331 42,301 56,867 50,141 48,184
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; RBV, ribavirin; SIM, 
simeprevir; SOF, sofosbuvir; SVR, sustained virologic response.
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In fact, the most frequently prescribed drug for GT 1b was 
PTVr/OBV/DSV±RBV, that is, the less-expensive option. Of 
note, in GT 1, the regimen based on PTVr+OBV+DSV±RBV 
demonstrated the lowest cost per SVR, granting a consider-
able saving of about 37%–38% with the major compara-
tor LDP+SOF±RBV. In a scenario of limited health care 
resources, this option would allow treatment for more patients 
while maintaining the same SVR rate.
The average cost per SVR is distinctly less than those 
observed in previous studies on first-generation DAAs, 
which ranged from €70,163 to €110,156 in the PAN study.39 
Noteworthy, first-generation DAAs were associated with a 
higher incidence of costs due to the management of adverse 
events (up to 8%),40 compared with the costs reported in 
our analysis (0.6%). These findings may lend support to the 
more favorable safety profile of second-generation DAAs, 
compared with previous regimens.41
All treatment regimens with RBV are far more expensive 
than the same regimen without this drug. In addition, mul-
tivariate analysis showed a significant difference in costs of 
care according to the HCV treatment, even after adjusting for 
the clinical characteristics at treatment initiation.
Our analysis confirms indirectly that the direct cost of the 
drug and – above all – RBV-associated toxicities with neces-
sary laboratory analysis increase the total expenditure. The 
only exception was GT 1b; however, three patients infected 
by this GT started treatment and stopped it after 2 weeks (two 
for toxicity) and 8 weeks (personal decision in one patient), 
therefore reducing the total cost.
Given the observed differences in SVR rates among dif-
ferent GTs, the correct determination of GT is of paramount 
importance in order to avoid errors in treatment selec-
tion42 and failure derived from inadequate therapy (about 
15%–40% of the estimated reduction in SVR attainment). 
In agreement with this, a recent Italian study has shown the 
cost- effectiveness of retesting HCV GT.43
The sensitivity analysis conducted on the cost per SVR 
clearly shows that the more pronounced the reduction in 
the cost of HCV treatment, the higher the savings for the 
NHS. On the other hand, the same decrease in costs for 
Table 4 Total and mean costs for different DAA treatments in patients according to HCV genotype Table 4 (Continued)
Anti-HCV regimen Genotype 1 Genotype 2 Genotype 3 Genotype 4
n Total Percentage Mean SD n Total Percentage Mean SD n Total Percentage Mean SD n Total Percentage Mean SD
SOF+RBV      31 1,269,035 40,937 2,620 45 1,855,475 48.70 41,233 630
SOF+LDP+RBV 45 1,886,982 24.96 41,933 7,217 7 300,893 14.29 42,985 5,345
SOF+SIM+RBV 38 2,319,038 30.68 61,027 875 13 787,608 37.40 60,585 992
PTVr/OBV+DSV+RBV 44 1,099,015 4.54 24,978 3,644
SOF+DCV+RBV 3 184,185 2.44 61,395 2,645      29 1,729,192 45.38 59,627 4,071 4 239,213 11.36 59,803 12
SOF+SIM 21 1,254,155 16.59 59,722 3,564 5 299,942 14.24 59,988 1,476
SOF+LDP 12 467,681 6.19 38,973 9,350 4 179,495 8.52 44,874 50
PTVr/OBV+RBV 10 239,209 11.36 23,921 662
PTVr/OBV+DSV 9 229,036 3.03 25,448 0
SOF+DCV 2 119,299 1.58 59,649 0      4 225,434 5.92 56,358 6,448 1 59,548 2.83 59,548 .
Total 174 7,559,389 100.00 43,445 15,430 31 1,269,035 100.00 40,937 2,620 78 3,810,101 100.00 48,847 9,405 44 2,105,908 100.00 47,862 15,001
p‑value <0.0001 – <0.0001 <0.0001
Abbreviations: DAA, direct antiviral agent; DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; 
RBV, ribavirin; SD, standard deviation; SIM, simeprevir; SOF, sofosbuvir.
Table 7 Cost per SVR (in €) and sensitivity analysis
























Note: *All costs issues varied at the same time and in the same percentage.
Abbreviations: DAA, direct antiviral agent; HCV, hepatitis C virus; SVR, sustained 
virologic response.





 laboratory and visits would only have a minimal influence. 
The  foreseeable reduction in RBV use will likely mini-
mize the impact of laboratory-driven and erythropoietin-
associated costs.36 Furthermore, the potential increase 
in SVR rate (2%–5%) with next-generation drugs might 
further decrease the cost for treatment by diminishing the 
failures, provided that the cost per SVR remains stable. On 
the other hand, sensitivity analysis suggests that, should 
the drug cost be cut by 50%, the cost per SVR would be 
€24,353. This cost corresponds to 5 years of management 
for one HCV-infected patient according to a recent study 
by Perrone et al.44
Moreover, in the context of price reduction, the drug-related 
cost (SOF+LDP €6,715±RBV; PTVr/OBV+DSV±RBV 
€12,833 PTVr/OBV+RBV €11,807±RBV) observed at the 
time of the drafting of this article (November 2016)45 was 
aligned with the sensitivity analysis of 50% of reduction. 
Therefore, considering these drug-related costs, the total 
cost is very similar to that of interferon-based therapy, but 
the latter is associated with a much lower SVR rate (ranging 
from 46% to 80%).46–51
By taking into consideration all the above, this dramatic 
cost reduction and its impact on the NHS budget could prob-
ably allow to expand the treatment criteria.
Our study is not without its limitations. For instance, treat-
ment costs for other antiviral agents in coinfected patients 
were not considered. Similarly, costs for radiology/ultrasound 
examination or fibroscan examinations before treatment were 
not taken into account, as well as those costs necessary during 
follow-up after SVR achievement. Even more importantly, 
our estimations were based according to the only available 
data, that is, those published by the Emilia-Romagna on 
its institutional website. However, Liguria benefits from 
a higher discount from total costs than Emilia-Romagna 
(more HCV patients have been treated in Liguria than in 
Emilia-Romagna), and therefore, the costs might result in an 
overestimation of those actually sustained in Liguria.
Despite these limitations, our analysis shows that the lead-
ing contributor to costs in the treatment of HCV infection is 
the antiviral regimen; an appropriate regimen selection could 
result in a great cost saving which can be reinvested to allow 
more patients to be treated.
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Supplementary materials
Table S1 Italian guidelines for the treatment of HCV at the time of study (Documento Società Italiana Studio Fegato-AISF December 
17, 2014)1
Regimen prescribed Genotype 1a Genotype 1b Genotype 2 Genotype 3 Genotype 4
PTVr/OBV+DSV±RBV PTVr/OBV+DSV+RBV for 
24 weeks
12 weeks with RBV No No No
SOF+LDP±RBV 12 weeks with RBV
24 weeks without RBV
12 weeks with RBV
24 weeks without RBV
No No 12 weeks with RBV
24 weeks without RBV
PTVr/OBV+RBV No No No No 24 weeks with RBV
SOF+DCV 12 weeks with RBV
24 weeks without RBV
12 weeks with RBV
24 weeks without RBV
12 weeks 
without RBV
24 weeks with RBV 
preferred regimen
12 weeks with RBV
24 weeks without RBV
SOF+RBV No No 16–20 weeks 24 weeks 
suboptimal
No
SOF+SIM 12 weeks with RBV
24 weeks without RBV
12 weeks with RBV
24 weeks without RBV
No No 12 weeks with RBV
24 weeks without RBV
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; RBV, ribavirin; SIM, 
simeprevir; SOF, sofosbuvir.
Table S2 Drug‑related costs (according to Regione Emilia‑Romagna)
Treatment regimen From January 1 to May 
31, 2015 
From June 1 to August 
31, 2015 
From September 1 to October 
31, 2015 
SOF+RBV 40,700+RBV 40,700+RBV 27,839+RBV
SOF+LDP+RBV 44,770+RBV 44,770+RBV 30,622+RBV
SOF+SIM+RBV 60,500+RBV 57,200+RBV 44,338+RBV
PTVr/OBV+DSV+RBV 25,300+RBV 25,300+RBV 25,300+RBV
SOF+DCV+RBV 59,400+RBV 59,400+RBV 46,539+RBV
SOF+SIM 60,500 57,200 44,338
SOF+LDP 44,700 44,700 30,622
PTVr/OBV+RBV 23,276+RBV 23,276+RBV 23,276+RBV
PTVr/OBV+DSV 25,300 25,300 25,300
SOF+DCV 59,400 59,400 46,539
Note: All costs are indicated in Euros.
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir.
Table S3 Laboratory code




 90.62.2 Complete blood cell count 3.35
 91.19.4 HCV RNA quantification 9.03
 90.09.2 AST 0.77
 90.04.5 ALT 0.77
 90.10.4 Bilirubin total 0.87
 90.10.5 Bilirubin direct/indirect 0.90
 90.25.5 GGT 0.83
 90.16.3 Creatinine 0.77
 90.23.5 Alkaline phosphatase 0.66





Note: All costs are indicated in Euros.
Abbreviations: HCV, hepatitis C virus; INR, international normalized ratio; GGT, gamma glutamil transferase; AST, aspartate transaminase; ALT, alanine transaminase.





Table S4 Other costs (indicated in Euros)
DRG code Clinical category Threshold Financial cost
203 Liver tumor (HCC) 35 days €4,085+175 a day each day >threshold
205 Liver cirrhosis complicated 27 days €3,760+157 a day per day >threshold
Abbreviation: DRG, diagnosis related group.
Table S5 Cost of drugs
Drug Cost
Albumin €43.49 per unit (VAT included)
Red blood cells €153 per unit (VAT included)
Erythropoietin (beta epoetin) 30,000 IU/mL €90.75 per unit (VAT included)
Ribavirin 200 mg €23.80 per unit (VAT included) 168 tablets





























n=76 n=52 n=51 n=44 n=36 n=26 n=16 n=10 n=9 n=7
Age, years 55 (51–71) 55 (52–59) 55 (52–61) 55 (51–63) 55 (52–55) 57 (51–62) 56 (51–64) 54 (51–59) 56 (51–60) 57 (54–62) 0.43
Gender (male) 55 (72.73) 41 (78.85) 38 (774.51) 32 (72.73) 31 (86.11) 8 (30.77) 13 (81.25) 7 (70.00) 4 (44.44) 4 (57.14) <0.0001
Fibrosis stage <0.0001
 1 1 (1.32) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (3.85) 1 (6.25) 0 (0.00) 1 (11.11) 0 (0.00)
 2 1 (1.32) 0 (0.00) 1 (1.96) 0 (0.00) 0 (0.00) 1 (3.85) 2 (12.50) 0 (0.00) 0 (0.00) 1 (14.29)
 3 19 (25.00) 2 (3.85) 8 (15.69) 6 (13.64) 1 (2.87) 9 (34.62) 7 (43.75) 4 (40.00) 6 (66.67) 2 (28.57)
 4 55 (72.37) 50 (96.15) 42 (82.35) 38 (86.36) 35 (97.22) 15 (57.69) 6 (37.50) 6 (60.00) 2 (22.22) 4 (57.14)
Genotype <0.0001
 1 0 (0.00) 45 (86.54) 38 (74.51) 44 (100.00) 3 (8.33) 21 (80.77) 12 (75.00) 0 (0.00) 9 (100.00) 2 (28.57)
 2 31 (40.79) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
 3 45 (59.21) 0 (0.00) 0 (0.00) 0 (0.00) 29 (80.56) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 4 (57.14)
 4 0 (0.00) 7 (13.46) 13 (25.49) 0 (0.00) 4 (11.11) 5 (19.23) 4 (25.00) 10 (100.00) 0 (0.00) 1 (14.29)
Comorbidities 37 (48.68) 39 (75.00) 27 (52.94) 22 (50.00) 24 (66.67) 4 (15.38) 7 (43.75) 2 (20.00) 2 (22.22) 4 (57.14) <0.0001
Previous 
treatment HCV
35 (46.05) 29 (55.77) 37 (72.55) 27 (61.36) 18 (50.00) 7 (26.92) 5 (31.25) 4 (40.00) 8 (88.89) 4 (57.14) 0.002
Note: Data are presented as median (interquartile range) for continuous variables and as frequency (%) for categorical variables.
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; RBV, ribavirin; SIM, 
simeprevir; SOF, sofosbuvir.
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Cost per care of DAAs in Linguria
Table S7 Correlates of the total cost: results of multivariate analyses
Variables b 95% CI p-value
HCV treatment
PTVr/OBV+DSV+RBV – – –
PTVr/OBV+DSV 1,863 −752; 4,477 0.16
PTVr/OBV+RBV −2,222 −4,980; 536 0.11
SOF+DCV 29,988 26,724; 33,253 <0.0001
SOF+DCV+RBV 31,922 29,161; 34,683 <0.0001
SOF+LDP 16,392 14,277; 18,506 <0.0001
SOF+LDP+RBV 16,954 15,537; 18,372 <0.0001
SOF+RBV 10,091 6,754; 13,429 <0.0001
SOF+SIM 30,481 28,415; 32,546 <0.0001
SOF+SIM+RBV 30,173 28,365; 31,981 <0.0001
Gender (female vs male) −510 −1,405; 386 0.26
Fibrosis grade
 1 – – –
 2 2,422 −2,067; 6,912 0.29
 3 2,152 −1,435; 5,738 0.24
 4 1,825 −1,772; 5,422 0.32
Genotype
 1 – – –
 2 2,563 −583; 5,708 0.11
 3 749 −1,891; 3,389 0.58
 4 573 −787; 1,932 0.41
Comorbidites (yes vs no) 623 −201; 1,446 0.14
Prior anti-HCV treatment (yes vs no) 712 −100; 1,525 0.09
Time start treatment −4,726 −5,682; −3,769 <0.0001
Abbreviations: CI, confidence interval; DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; 
RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir.
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